Overview

Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The main objective was to investigate the effect of concurrent dosing of 10 mg ramipril and 80 mg telmisartan on the multiple-dose pharmacokinetics of telmisartan and ramipril. Therefore the relative bioavailability of telmisartan and ramipril given in combination was determined in comparison with either telmisartan or ramipril given alone.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Ramipril
Telmisartan